Latest Breaking News On - Neurobo pharmaceuticals - Page 4 : comparemela.com

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification Full Data Readout Expected in the Second Half of.

United kingdomMarshallh woodworthMichael millerNeurobo pharmaceuticals incPrnewswire neurobo pharmaceuticals incSafety review committeeDonga st coRx communications groupNeurobo pharmaceuticalsBlinded safety review completedClinical trial conductRecommending trial continue withoutData readout expectedSecond halfG protein coupled receptorHyung heon kim

NeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%

Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO) announced Wednesday the receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241 can continue without modification following a blinded safety review of the first six months of study conduct.

Neurobo pharmaceuticals incSafety review committeeNeurobo pharmaceuticalsG protein coupled receptorMetabolic dysfunction associated steatohepatitisIotechnology company neurobo pharmaHase 2a trial of da 1241

NeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gains

Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO), Thursday announced that it has received first site Institutional Review Board or IRB approval for Alexander Prezioso, Investigator, Clinical Pharmacology of Miami, to proceed with the Phase 1 clinical trial of DA-1726 for the treatment of obesity.

United statesAlexander preziosoNeurobo pharmaceuticals incNeurobo pharmaceuticalsInstitutional review boardClinical pharmacology

NeuroBo Pharmaceuticals (NRBO) Receives First Site IRB Approval for Its Phase 1 Trial of DA-1726

NeuroBo Pharmaceuticals (NRBO) Receives First Site IRB Approval for Its Phase 1 Trial of DA-1726
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlexander preziosoNeurobo pharmaceuticals inc nasdaqNeurobo pharmaceuticalsInstitutional review boardClinical pharmacologyIcheon kimChief executive officer

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today.

United statesUnited kingdomMichael millerAlexander preziosoMarshallh woodworthDonga st coNeurobo pharmaceuticalsNeurobo pharmaceuticals inc nasdaqNeurobo pharmaceuticals incFirst patient expectedSecond quarterInstitutional review boardClinical pharmacologyHyung heon kimChief executive officerMetabolic dysfunction associated steatohepatitis